Introduction: Squamous cell carcinomas of the head and neck, including laryngeal cancer, rank sixth in prevalence according to world statistics from developed countries. The role of laryngopharyngeal reflux as one of the risk factors for the development of laryngeal cancer remains controversial and needs further study.
Objective: To analyze and compare clinical manifestations and morphological data in patients with laryngeal cancer T1-2N0M0 with LPR.
Materials and methods: 87 patients with laryngeal cancer of the I-II stage T1-2N0M0. For the purpose of screening diagnostics of LPR, modified visualanalogue scales RSI and RFS were used,24-hour pH-monitoring was performed. To conduct a histopathological study, samples of surgical material were selected from 8 patients with laryngeal cancer of the I-II stage T1-2N0M0 with LPR; 8 patients with laryngeal cancer – without LPR and 8 patients with benign neoplasms of the larynx with LPR.
Results: When analyzing the results of the examination, the RSI index exceeded “9” in 39 (44.8%) patients.
According to 24-hour pH monitoring, the presence of LPR was diagnosed in 32 (36.8%) examined patients with morphologically verified squamous cell carcinoma of the larynx, which made up the study group. In 6 (75.0%) patients from the comparison group, areas covered by stratified squamous epithelium were determined within the mucous membrane, in 5 (62.5%) patients, transition zones containing both stratified squamous and single-layered multilayer ciliated were determined epithelium. The nature and intensity of lymphohistiocytic infiltration was more expressed in patients with associated LPR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.